Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) produce a statistically significant but clinically modest reduction in systolic blood pressure (SBP) compared to placebo, with effects ranging from -1.46 to -3.40 mmHg.
GLP-1 medications (like Ozempic or Wegovy) consistently lower systolic blood pressure by a small but measurable amount (1-3 mmHg). This benefit occurs regardless of whether you have diabetes. It is not a substitute for blood pressure medication, but it is a favorable side effect that supports heart health.
Compared to placebo, GLP-1RAs modestly reduced SBP (semaglutide: MD -3.40... liraglutide: MD -2.61... dulaglutide: MD -1.46... and exenatide: MD -3.36...)
Why this rating
Meta-analysis of 63 RCTs with >53,000 participants provides high statistical power, though heterogeneity is noted.
Source
Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
Frederick Berro Rivera et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15529
More from this paper
- GLP-1 receptor agonists generally do not significantly reduce diastolic blood pressure (DBP), with the exception of exenatide.Good
- The magnitude of systolic blood pressure reduction with GLP-1 RAs is directly associated with changes in body weight, BMI, and HbA1c, suggesting these metabolic improvements drive the BP benefit.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →